Current Treatment Landscape of HER2-Positive Metastatic Breast Cancer and Phase 3 Trial Overview

Dr. Ami Shah introduces the CancerNetwork Around the Practice program focusing on evolving clinical perspectives in HER2-positive breast cancer, joined by Dr. Megan Kruse from Cleveland Clinic and Dr. Ruta Rao from Rush University Medical Center. The discussion addresses interpreting emerging data, treatment strategies, and multidisciplinary care for patients with HER2-positive disease.

Dr. Rao provides comprehensive overview of recent Phase 3 trials demonstrating trastuzumab deruxtecan's (T-DXd) efficacy across multiple settings. DESTINY-Breast09 challenged the standard CLEOPATRA regimen in first-line metastatic disease, comparing T-DXd plus pertuzumab against taxane, trastuzumab, and pertuzumab (THP). The study was designed as a three-arm trial, though results for T-DXd alone remain pending.

The combination demonstrated significant improvement in median progression-free survival: 40.7 months versus 26.9 months for THP, with a hazard ratio of 0.56. This represents both statistically significant and clinically meaningful advancement for patients with first-line HER2-positive metastatic breast cancer.

DESTINY-Breast11 evaluated T-DXd in the neoadjuvant setting as a 3-arm trial comparing T-DXd followed by THP, dose-dense doxorubicin/cyclophosphamide followed by THP, and T-DXd alone. The monotherapy arm was discontinued due to insufficient pathologic complete response rates.

High-risk patients (T3 disease with any nodal status or node-positive disease, including inflammatory cases) were enrolled. The study achieved improved pathologic complete response rates: 67% for T-DXd followed by THP versus 56% for the standard arm, representing an 11% difference with established prognostic implications.

DESTINY-Breast05 challenged the established KATHERINE algorithm for adjuvant treatment of residual disease after neoadjuvant therapy, comparing 14 cycles of T-DXd versus TDM-1. The study demonstrated improved 3-year invasive disease-free survival (92% versus 84%), with favorable outcomes across disease-free survival, distant relapse-free survival, and notably brain metastasis-free survival endpoints.